|
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Notably, disrupting Nrh/IP3R complexes by BH4 mimetic peptides was sufficient to inhibit the growth of breast cancer cells <i>in vitro</i> and <i>in vivo</i> Taken together, our results highlighted Nrh as a novel prognostic marker and a candidate therapeutic target for late stage breast cancers that may be addicted to Nrh.<b>Significance:</b> These findings offer a comprehensive molecular model for the activity of Nrh/BCL2L10, a little studied antiapoptotic molecule, prognostic marker, and candidate drug target in breast cancer.<i>Cancer Res; 78(6); 1404-17.©2018 AACR</i>.
|
29330143 |
2018 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Human cancer pathway PCR array was employed to explore the genes regulated by BCL2L10 in HCC.
|
27770580 |
2017 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
BCLB protein expression was significantly correlated with HBV status (p = 0.036), AFP (p = 0.048), tumor size (p = 0.006), and TNM stage (p = 0.022).
|
28259820 |
2017 |
|
Malignant Neoplasms
|
0.050 |
GeneticVariation
|
group |
BEFREE |
This is the first report on the prevalence of BCL2L10 Leu21Arg polymorphism in myeloid malignancies.
|
24047476 |
2014 |
|
Neoplasms
|
0.050 |
GeneticVariation
|
group |
BEFREE |
The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes.
|
24047476 |
2014 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
The protein encoded by one of these less potent genes, BCL2L10/BCLb, was recently shown to vary dramatically in many primary human cancers by immunohistochemistry, and the protein levels were inversely correlated with survival in patients with several cancer types.
|
22233804 |
2012 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
The pro-apoptotic effect of BCL2L10 and growth promotion by BCL2L10 siRNA in gastric cancer cells suggest that it may be a tumour suppressor.
|
21171085 |
2011 |
|
Neoplasms
|
0.050 |
PosttranslationalModification
|
group |
BEFREE |
Correspondingly, in primary patient samples, BCL2L10 was hypermethylated in 45% of AML, 43% of therapy-related myeloid neoplasms, 12% of MDS, and in none of the controls.
|
21077739 |
2010 |
|
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
We investigated Bcl-B expression in normal human tissues and several types of human epithelial and nonepithelial malignancy by immunohistochemistry, correlating results with tumor stage, histologic grade, and patient survival.
|
18483366 |
2008 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Conversely, although overexpressed in many gastric cancers, Bcl-B tended to correlate with better outcome (P = 0.01) and more differentiated tumor histology (P < 0.0001).
|
18483366 |
2008 |
|
MYELODYSPLASTIC SYNDROME
|
0.040 |
Biomarker
|
group |
BEFREE |
This study included patients with IPSS lower-risk MDS from the DRAMA (An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome; NCT01400633) and DIVA (A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome; NCT01041846) studies, which were prospective observational studies on the efficacy and safety of decitabine treatment in patients with MDS.
|
31375393 |
2019 |
|
MYELODYSPLASTIC SYNDROME
|
0.040 |
Biomarker
|
group |
BEFREE |
BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia.
|
28514758 |
2017 |
|
MYELODYSPLASTIC SYNDROME
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Carriers of the BCL2L10-21Arg variant have a reduced risk of developing t-MN and de novo MDS.
|
24047476 |
2014 |
|
MYELODYSPLASTIC SYNDROME
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Therefore, systematic determination of BCL2L10 expression could be of great interest in newly diagnosed and AZA-treated MDS patients.
|
22577154 |
2012 |
|
Miller Dieker syndrome
|
0.030 |
Biomarker
|
disease |
BEFREE |
This study included patients with IPSS lower-risk MDS from the DRAMA (An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome; NCT01400633) and DIVA (A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome; NCT01041846) studies, which were prospective observational studies on the efficacy and safety of decitabine treatment in patients with MDS.
|
31375393 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Notably, disrupting Nrh/IP3R complexes by BH4 mimetic peptides was sufficient to inhibit the growth of breast cancer cells <i>in vitro</i> and <i>in vivo</i> Taken together, our results highlighted Nrh as a novel prognostic marker and a candidate therapeutic target for late stage breast cancers that may be addicted to Nrh.<b>Significance:</b> These findings offer a comprehensive molecular model for the activity of Nrh/BCL2L10, a little studied antiapoptotic molecule, prognostic marker, and candidate drug target in breast cancer.<i>Cancer Res; 78(6); 1404-17.©2018 AACR</i>.
|
29330143 |
2018 |
|
Liver carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Furthermore, overexpressing Bcl2L10 was able to partly reverse the promoting effects of miR-18a on HCC cell progression.
|
30519035 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.030 |
Biomarker
|
disease |
BEFREE |
In this study, we assessed prospectively by flow cytometry the prognostic value of BCL2L10 positive bone marrow mononuclear cells in 70 patients (42 MDS and 28 AML), prior to AZA treatment.In patients with baseline marrow blasts below 30%, the baseline percentage of bone marrow BCL2L10 positive cells inversely correlated with response to AZA and OS independently of the International Prognostic Scoring System (IPSS) and IPSS-revised (IPSS-R).
|
28514758 |
2017 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Human cancer pathway PCR array was employed to explore the genes regulated by BCL2L10 in HCC.
|
27770580 |
2017 |
|
Liver carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
HCC cells transfected with BCL2L10 revealed an increased cell proportion arrested at G2/M phase, concomitant with a reduction in the cell proportion in S-phase as compared with control cells.
|
27770580 |
2017 |
|
Liver carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Thus, epigenetic suppression of BCLB expression is involved in HCC development, which might have therapeutic implications for HCC patients.
|
28259820 |
2017 |
|
Miller Dieker syndrome
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Carriers of the BCL2L10-21Arg variant have a reduced risk of developing t-MN and de novo MDS.
|
24047476 |
2014 |
|
Leukemia, Myelocytic, Acute
|
0.030 |
Biomarker
|
disease |
BEFREE |
In addition, we showed that the proportion of BCL2L10 positive bone marrow cells can predict overall survival in MDS or AML patients.
|
22577154 |
2012 |
|
Miller Dieker syndrome
|
0.030 |
Biomarker
|
disease |
BEFREE |
BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients.
|
22577154 |
2012 |
|
Leukemia, Myelocytic, Acute
|
0.030 |
PosttranslationalModification
|
disease |
BEFREE |
Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.
|
21077739 |
2010 |